The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic bendamustine, marking it as the first of its kind in China for the treatment of malignant tumors. Bendamustine, a bifunctional nitrogen mustard derivative, is recognized for its ability to induce cell death through multiple mechanisms, thereby exhibiting anti-tumor effects.
This next-generation anti-tumor drug is noted for its low toxicity, high activity, broad anti-tumor spectrum, patient-friendly tolerance, and suitability for long-term use. It is particularly indicated for the treatment of indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or after treatment with rituximab or rituximab-containing regimens. In the US and Europe, bendamustine is recommended as a first or second-line treatment for various hematologic malignancies, either as a monotherapy or in combination with other drugs.- Flcube.com
